Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 chemotherapy study in non-resectable pancreatic cancer (irinotecan + oxaliplatin + gemcitabine)
2014-003510-82Phase 3Terminated
- Sponsor
- Unicancer
- Start
- Jan 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of irinotecan, oxaliplatin and gemcitabine in pancreatic cancer (PC), sponsored by Unicancer. Started Jan 2015; status: terminated.
02
Drugs
irinotecanoxaliplatingemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-003510-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003510-82.